Subscribe
istock-839222794-nicoelnino-1
NicoElnino / iStockphoto.com
13 November 2018Americas

CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology

Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
CRISPR Therapeutics unites with ViaCyte to treat diabetes
19 September 2018   Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.
Americas
Vertex and CRISPR Therapeutics announce research partnership
26 October 2015   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have agreed a research collaboration to discover and develop new treatments for genetic causes of human diseases.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Americas
CRISPR Therapeutics unites with ViaCyte to treat diabetes
19 September 2018   Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.
Americas
Vertex and CRISPR Therapeutics announce research partnership
26 October 2015   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have agreed a research collaboration to discover and develop new treatments for genetic causes of human diseases.

More on this story

Americas
CRISPR Therapeutics unites with ViaCyte to treat diabetes
19 September 2018   Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.
Americas
Vertex and CRISPR Therapeutics announce research partnership
26 October 2015   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have agreed a research collaboration to discover and develop new treatments for genetic causes of human diseases.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York